These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 94352)
41. Synthetic peptides against foot-and-mouth disease--immunization with VP1-peptides of type O1-Kaufbeuren. Liebermann H; Holl U; Reimann I; Nöckler A; Schäfer D; Thalmann G; Dölling R Arch Exp Veterinarmed; 1990; 44(6):883-90. PubMed ID: 1966360 [TBL] [Abstract][Full Text] [Related]
42. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1. Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609 [TBL] [Abstract][Full Text] [Related]
43. Escape mutants of foot-and-mouth disease virus selected by monoclonal antibodies directed to a trypsin-sensitive neutralization epitope. Das BR; Pattnaik B; Venkataramanan R; Rai DV Acta Virol; 1997 Jun; 41(3):131-8. PubMed ID: 9385400 [TBL] [Abstract][Full Text] [Related]
45. Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats. Chow M; Baltimore D Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7518-21. PubMed ID: 6296837 [TBL] [Abstract][Full Text] [Related]
46. [Antigenic structure of the foot-and-mouth disease virus. III. Immunogenic properties of synthetic peptides of the sequence of the immunodominant region of VP1 proteins of the O1K and A22 strains of foot-and-mouth virus]. Surovoĭ AIu; Gel'fanov VM; Vol'pina OM; Ivanov VT; Chepurkin AV; Chepurkin AV; Ivaniushchenkov VM; Driagalin NN; Burdov AN Bioorg Khim; 1989 Sep; 15(9):1185-92. PubMed ID: 2480134 [TBL] [Abstract][Full Text] [Related]
47. Radioimmunoassay for detection of VP1 specific neutralizing antibodies of foot and mouth disease virus. Patzer EJ; Jackson ML; Moore DM J Virol Methods; 1985 Jan; 10(1):29-37. PubMed ID: 2982892 [TBL] [Abstract][Full Text] [Related]
48. A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice. Zamorano P; Wigdorovitz A; Perez-Filgueira M; Carrillo C; Escribano JM; Sadir AM; Borca MV Virology; 1995 Oct; 212(2):614-21. PubMed ID: 7571431 [TBL] [Abstract][Full Text] [Related]
49. [Antigenic structure of the foot-and-mouth-disease virus. I. Synthesis of protective peptides from the major immunogenic region of VP1 protein of foot-and-mouth virus type O1K]. Surovoĭ AIu; Vol'pina OM; Snetkova EV; Volkova TD; Ivanov VT Bioorg Khim; 1988 Oct; 14(10):1352-62. PubMed ID: 2852937 [TBL] [Abstract][Full Text] [Related]
51. A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles. Parry NR; Syred A; Rowlands DJ; Brown F Immunology; 1988 Aug; 64(4):567-72. PubMed ID: 2844657 [TBL] [Abstract][Full Text] [Related]
52. Epitope mapping of the outer structural protein VP1 of three different serotypes of foot-and-mouth disease virus. Meloen RH; Barteling SJ Virology; 1986 Feb; 149(1):55-63. PubMed ID: 2418582 [TBL] [Abstract][Full Text] [Related]
53. Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virions. Blondel B; Akacem O; Crainic R; Couillin P; Horodniceanu F Virology; 1983 Apr; 126(2):707-10. PubMed ID: 6190311 [TBL] [Abstract][Full Text] [Related]
54. Induction of neutralizing antibodies by all three structural poliovirus polypeptides. Dernick R; Heukeshoven J; Hilbrig M Virology; 1983 Oct; 130(1):243-6. PubMed ID: 6314647 [TBL] [Abstract][Full Text] [Related]
55. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643 [TBL] [Abstract][Full Text] [Related]
56. Orientation of epitopes influences the immunogenicity of synthetic peptide dimers. Cox JH; Ivanyi J; Young DB; Lamb JR; Syred AD; Francis MJ Eur J Immunol; 1988 Dec; 18(12):2015-9. PubMed ID: 2464496 [TBL] [Abstract][Full Text] [Related]
57. Host cell selection of antigenic variants of foot-and-mouth disease virus. Bolwell C; Brown AL; Barnett PV; Campbell RO; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ J Gen Virol; 1989 Jan; 70 ( Pt 1)():45-57. PubMed ID: 2471782 [TBL] [Abstract][Full Text] [Related]
58. Protection conferred by TrpE fusion proteins containing portions of the C-terminal region of capsid protein VP1 of foot-and-mouth disease virus. Giavedoni LD; Kaplan G; Marcovecchio F; Piccone ME; Palma EL J Gen Virol; 1991 Apr; 72 ( Pt 4)():967-71. PubMed ID: 1849980 [TBL] [Abstract][Full Text] [Related]
59. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Mayr GA; Chinsangaram J; Grubman MJ Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121 [TBL] [Abstract][Full Text] [Related]
60. Serological and immunological relations between the 146S and 12S particles of foot-and-mouth disease virus. Cartwright B; Chapman WG; Brown F J Gen Virol; 1980 Oct; 50(2):369-75. PubMed ID: 6257825 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]